This study will evaluate the abuse potential of ALKS 5461.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
56
Sublingual tablets, single administration
Sublingual tablets, single administration
Sublingual tablets, single administration
Alkermes Investigational Site
Overland Park, Kansas, United States
Pharmacodynamics: Abuse potential measured by visual analog scales (VAS)
Time frame: Approximately 14 weeks
Safety: Incidence of adverse events (AEs)
Time frame: Up to 14 weeks
Pharmacokinetics: Plasma concentrations of ALKS 5461
Time frame: Up to 14 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.